NCT05587751 is a NA clinical trial of Spirometry in Hormonal Gender-Affirming Therapy, sponsored by Mayo Clinic.

Who is sponsoring NCT05587751?

NCT05587751 is sponsored by Mayo Clinic.

What drugs are being tested in NCT05587751?

Interventions in NCT05587751: Spirometry, Plethysmography.

What condition does NCT05587751 study?

NCT05587751 studies Hormonal Gender-Affirming Therapy.

Is NCT05587751 still recruiting?

NCT05587751 is currently recruiting now. Last updated 15 May 2026.

Last reviewed 2026-05-15 · How we verify

NCT05587751

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Impact of Gender-Affirming Treatments on Pulmonary Function in Transgender and Gender Diverse (TGD) Patients

Recruiting now NA Last updated 15 May 2026

What this trial tests

NA trial testing Spirometry in Hormonal Gender-Affirming Therapy in 44 participants. Currently enrolling.

Timeline

1 February 2023

Primary endpoint
1 July 2027

1 July 2027

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	44
Start date	1 February 2023
Primary completion	1 July 2027
Estimated completion	1 July 2027
Sites	1 location across United States

Drugs / interventions tested

Spirometry
Plethysmography

Conditions studied

Hormonal Gender-Affirming Therapy — all drugs for Hormonal Gender-Affirming Therapy →

Sponsor

Mayo Clinic

Who can join

14 and older, any sex, with Hormonal Gender-Affirming Therapy. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in lung volume (Total Lung Capacity, Vital Capacity, Functional Residual Capacity, Residual Volume)
Time frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
The longitudinal changes in lung volumes after both masculinizing and feminizing hormone therapy in transgender and gender diverse (TGD) patients.
Change in forced expiratory volume
Time frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
Measured by spirometry to determine the volume of air that can be exhaled in 1 second with a forced breath
Change in forced vital capacity
Time frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
Measured by spirometry to determine the maximal amount of air that can be forcibly exhaled from the lungs after a full inhale, reported as liters (L)
Change in peak expiratory flow
Time frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
Measured by a peak flow meter is the maximum forced expiratory flow, reported in liter per minute (L/min)
Change in maximal mid-expiratory flow rate
Time frame: Baseline, 6-month Follow-Up, 12-month Follow-Up, 18-month Follow-Up
Measured by spirometry to determine the rate of airflow where half of the forced vital capacity is exhaled

Sponsor's own description

The purpose of this research study is to evaluate whether undergoing gender affirming care will impact the way the lungs function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Spirometry

Trials testing the same drug.

NCT07351916 — Remission in Adults With Mild-to-moderate Asthma in Thailand · recruiting
NCT07328035 — Remission in Adults With Severe Asthma in Thailand · recruiting
NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
NCT07253883 — A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPD · not yet recruiting
NCT06626178 — Development of an Artificial Intelligence Model for the Identification and Prevention of Smoking-related Diseases. · NA · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05587751 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 15 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05587751.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing